Abstract
In this issue of Blood, Fandy and colleagues describe the results of a trial in which leukemia patients were treated with 5-azacytidine (5-azaC) and the HDAC inhibitor, entinostat. 1 Their results confirm the therapeutic efficacy of these agents but also demonstrate that we have much to learn about the mechanism of action of agents that target the epigenome.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2569-2570 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 114 |
| Issue number | 13 |
| DOIs |
|
| State | Published - 2009 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology